Vontobel Holding Ltd. Sells 1,788 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Vontobel Holding Ltd. lowered its position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 25.7% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 5,172 shares of the specialty pharmaceutical company’s stock after selling 1,788 shares during the quarter. Vontobel Holding Ltd.’s holdings in Jazz Pharmaceuticals were worth $576,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. CFM Wealth Partners LLC boosted its holdings in Jazz Pharmaceuticals by 59.5% during the third quarter. CFM Wealth Partners LLC now owns 4,184 shares of the specialty pharmaceutical company’s stock worth $504,000 after purchasing an additional 1,560 shares during the last quarter. Benson Investment Management Company Inc. acquired a new position in shares of Jazz Pharmaceuticals during the 3rd quarter worth about $4,082,000. Wedge Capital Management L L P NC acquired a new position in shares of Jazz Pharmaceuticals during the 3rd quarter worth about $32,497,000. Exchange Traded Concepts LLC grew its holdings in shares of Jazz Pharmaceuticals by 21.8% in the 3rd quarter. Exchange Traded Concepts LLC now owns 6,890 shares of the specialty pharmaceutical company’s stock valued at $768,000 after acquiring an additional 1,233 shares in the last quarter. Finally, Inspire Investing LLC acquired a new stake in shares of Jazz Pharmaceuticals in the third quarter valued at about $312,000. 89.14% of the stock is owned by institutional investors.

Jazz Pharmaceuticals Stock Performance

Shares of NASDAQ:JAZZ opened at $113.12 on Tuesday. Jazz Pharmaceuticals plc has a 1 year low of $99.06 and a 1 year high of $134.48. The stock has a market capitalization of $7.13 billion, a price-to-earnings ratio of 23.32, a price-to-earnings-growth ratio of 1.34 and a beta of 0.57. The company has a debt-to-equity ratio of 1.36, a current ratio of 2.37 and a quick ratio of 2.02. The company’s 50 day simple moving average is $110.98 and its 200 day simple moving average is $109.67.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings results on Wednesday, July 31st. The specialty pharmaceutical company reported $4.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.80 by $0.87. Jazz Pharmaceuticals had a return on equity of 28.65% and a net margin of 10.10%. The company had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1 billion. As a group, research analysts predict that Jazz Pharmaceuticals plc will post 16.03 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, SVP Mary Elizabeth Henderson sold 1,410 shares of the firm’s stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $108.30, for a total value of $152,703.00. Following the sale, the senior vice president now directly owns 14,531 shares in the company, valued at approximately $1,573,707.30. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 4.20% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently commented on JAZZ. UBS Group reduced their price target on Jazz Pharmaceuticals from $117.00 to $113.00 and set a “neutral” rating for the company in a research report on Tuesday, July 2nd. Wells Fargo & Company reduced their price target on Jazz Pharmaceuticals from $140.00 to $120.00 and set an “equal weight” rating for the company in a report on Thursday, August 1st. Royal Bank of Canada increased their price target on Jazz Pharmaceuticals from $174.00 to $175.00 and gave the company an “outperform” rating in a research note on Friday, October 4th. Needham & Company LLC reaffirmed a “buy” rating and set a $205.00 price objective on shares of Jazz Pharmaceuticals in a research report on Tuesday, September 10th. Finally, Robert W. Baird dropped their price objective on shares of Jazz Pharmaceuticals from $160.00 to $154.00 and set an “outperform” rating on the stock in a research report on Thursday, August 1st. Three research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $173.14.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.